An interventional study of Placebo Group and Laser Group in Tendinopathy, sponsored by Universidad Pontificia de Salamanca. Completed at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by Universidad Pontificia de Salamanca · Not applicable, Interventional, and Treatment
Tendinopathy is an inflammatory process that occurs in and around the tendon when both are affected by a certain injury. In the case of the supraspinatus muscle it is one of the most frequent causes of shoulder pain. To test the efficacy of laser treatment in reducing shoulder pain caused by supraspinatus muscle tendinopathy. A randomized controlled clinical trial (RCT) was carried out in which a physiotherapy intervention was performed using therapeutic laser for three months, to observe the influence on the pain generated by supraspinatus muscle tendinopathy in the shoulder.
413 studies on the registry are indexed under Tendinopathy; 64 are open to participants now.
This study's enrollment of 40 is below the median of 50 across 339 interventional studies indexed under Tendinopathy.
Browse Tendinopathy studies →Universidad Pontificia de Salamanca is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Laser treatment on tendinophaty shoulder.
Device: Laser Group
Placebo treatment on tendinophaty shoulder.
Device: Placebo Group
A placebo treatment is carried out on the shoulder, simulating the application of the laser.
Therapeutic laser treatment is performed on the shoulder.
intensity of pain.
measured using the VAS scale, where 0 is the least possible pain and 10 is the greatest possible pain
Time frame: 3 months
Range of motion
Shoulder mobility in the joint ranges of flexion, extension, abduction, adduction, and external and internal rotation. Measurement in degrees using a goniometer.
Time frame: 3 months
Patient quality of life
DASH questionnaire The score ranges from 0, which is equivalent to having no disability, to a maximum of 100, which is equivalent to having a very severe functional limitation.
Time frame: 3 months
Plan to share: Yes — De-identified individual participant data, including the data dictionary, will be shared with qualified researchers. The shared IPD will include the data needed to reproduce the study findings, such as the de-identified participant-level data underlying the results reported in the publication.
Supporting information: Study protocol, Icf
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad Pontificia de Salamanca